康臣药业2025 中期报告

Kidney Medicines腎科藥物 Gynaecology andPaediatric Medicines婦兒藥物 Contrast Medium對比劑 Interim Report2025中 期 報 告 Dermatologic Medicines皮膚科藥物 Orthopedics Medicines骨科藥物 Hepatobiliary Medicines肝膽藥物 Gastroenterology Medicines消化系統藥物 Contents目錄 Corporate Information2Financial Highlights6Management Discussion and Analysis7Consolidated Statement of Profit or Loss21Consolidated Statement of Profit or Loss and Other Comprehensive Income22Consolidated Statement of Financial Position23Consolidated Statement of Changes in Equity25Condensed Consolidated Cash Flow Statement29Notes to the Unaudited Interim Financial Report31Review Report62Other Information64 公司資料Corporate Information DIRECTORS 董事 執行董事 Executive Directors 202548 Mr. An Meng(Chairman and Chief Executive Officer)Professor Zhu QuanMr. Young Yuk Chuen David(appointed on 8 April 2025) 非執行董事 Non-Executive Director Dr. Zhang Lihua 獨立非執行董事 Independent Non-Executive Directors 20252242025482025224 Mr. Feng ZhongshiProfessor Li YikaiMr. Li Zhuoguang(appointed on 24 February 2025)Mr. Duan Weiwu(appointed on 8 April 2025)Ms. Chen Yujun(resigned, effective from 24 February 2025) 審核委員會 AUDIT COMMITTEE 20252 2420252 24202548202548 Mr. Li Zhuoguang(Committee Chairman)(appointed on 24 February 2025)Ms. Chen Yujun(Committee Chairlady)(resigned, effective from 24 February 2025)Professor Li YikaiMr. Duan Weiwu(appointed on 8 April 2025)Mr. Feng Zhongshi(resigned, effective from 8 April 2025) 提名委員會 NOMINATION COMMITTEE 20254820256202025224202522420254 820256 20 Professor Li Yikai(Committee Chairman)Mr. Duan Weiwu(appointed on 8 April 2025)Dr. Zhang Lihua(appointed on 20 June 2025)Ms. Chen Yujun(resigned, effective from 24 February 2025)Mr. Li Zhuoguang(appointed on 24 February 2025,and resigned, effective from 8 April 2025)Mr. An Meng(resigned, effective from 20 June 2025) 薪酬委員會 REMUNERATION COMMITTEE 20252 2420252 24 Mr. Feng Zhongshi(Committee Chairman)Mr. An MengMr. Li Zhuoguang(appointed on 24 February 2025)Ms. Chen Yujun(resigned, effective from 24 February 2025) 環境、社會及管治委員會 ENVIRONMENTAL, SOCIAL AND GOVERNANCECOMMITTEE 20254 820252 2420252 2420254 8 Mr. An Meng(Committee Chairman)Mr. Feng ZhongshiMr. Young Yuk Chuen David(appointed on 8 April 2025)Ms. Chen Yujun(resigned, effective from 24 February 2025)Mr. Li Zhuoguang(appointed on 24 February 2025,and resigned, effective from 8 April 2025) 公司秘書 COMPANY SECRETARY Mr. Gao Haien AUTHORISED REPRESENTATIVES FOR THEPURPOSE OF THE LISTING RULES 就上市規則而言的授權代表 Mr. An MengMr. Gao Haien 核數師 AUDITOR 108 KPMGPublic Interest Entity Auditor registered in accordancewith the Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater Road, Central, Hong Kong 法律顧問（香港法律） LEGAL ADVISER (AS TO HONG KONG LAW) 1922 Li & Partners22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong 公司資料Corporate Information 註冊地址 REGISTERED ADDRESS Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands 中國總部 HEADQUARTERS IN THE PRC 71 71, Dongpeng Avenue, Eastern sectionGuangzhou Economic and Technological Development DistrictGuangzhou, PRC 香港主要營業地點 PRINCIPAL PLACE OF BUSINESS IN HONG KONG 1922 22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong LIAISON OFFICE IN HONG KONG 香港聯絡辦公室 62803 Room 803Wing On Plaza62 Mody RoadTsimshatsui, Kowloon PRINCIPAL BANKERS 主要往來銀行 主要證券登記處 PRINCIPAL SHARE REGISTRAR Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands 香港證券登記分處 HONG KONG BRANCH SHARE REGISTRAR 183171712-1716 Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17th Floor, Hopewell Centre183 Queen’s Road EastWanchai, Hong Kong 公司網站www.chinaconsun.com COMPANY WEBSITE www.chinaconsun.com 股份代號1681 STOCK CODE 1681 財務࿜要Financial Highlights 管理層ী論及分ؓManagement Discussion and Analysis 34 Thefollowing discussion and analysis should be read inconjunction with the unaudited interim financial report of theGroup.The interim financial report of the Group has beenpreparedin accordance with HKAS 34,Interim FinancialReporting. 業務與財務回顧 BUSINESS AND FINANCIAL REVIEW 財務回顧 Financial Review Revenue Forthe six months ended 30 June 2025,the Group’srevenue was RMB1,568,588,000, representing an increase ofapproximately 23.7% as compared with RMB1,268,549,000 forthe same period of 2024. 20256301,568,588,00020241,268,549,00023.7% 28.0%尿毒清17.5%22.0%2.1%19.7%4.6%5.4% Categorizedby product lines,sales of kidney medicinesrecorded an increase of approximately 28.0% as comparedwiththe same period last year,among which,UremicClearanceGranules(“UCG”)remained the Group’s keyproductand maintained its leading position in the market;salesof gynaecology and paediatrics medicines recordedanincrease of approximately 17.5%as c